Table 1.
In Vivo Efficacy of diallyl trisulfide against cancer in experimental rodents.
| Species (sex) | Model | DATS dose/route | Outcome | Ref. |
|---|---|---|---|---|
| A/J mice (female) | BP1-induced | 20 μmol DATS2, oral | Forestomach cancer- 85% inhibition | 17 |
| Lung adenoma- no effect | 17 | |||
| A/J mice (female) | BP-induced | 25 μmol DATS, oral | Forestomach cancer- 86% inhibition | 18 |
| BALB/c nude mice (male) | PC-3 xenograft (subcutaneous) |
6 μmol DATS, oral, three times/wk |
Prostate tumor growth inhibition | 19 |
| BALB/c nude mice (male) | PC-3 xenograft (orthotopic) |
40 mg/kg DATS, oral, five times/wk |
Prostate tumor growth inhibition and potentiation of TRAIL efficacy |
20 |
| BALB/c nude mice (male) | HepG2 xenograft (orthotopic) |
1.5 mg/kg, i.v, DATS-PBCA-NP3 |
Hepatocellular cancer growth inhibition |
21 |
| BALB/c nude mice (female) | CT26 allograft | 50 mg/kg DATS, i.p., every fourth day |
Colon cancer growth inhibition | 22 |
| TRAMP4 mice (male) | Spontaneous | 1 or 2 mg DATS/mouse, oral, thrice/wk for 13 wk |
Inhibition of incidence and burden of poorly-differentiated prostate cancer |
23 |
| ICR mice (female) | two-stage skin papilloma model (DMBA5 + TPA6) |
5 or 25 μmol DATS, topical, twice/wk for 20 wk |
Inhibition of skin papilloma incidence (25 μmol DATS) and multiplicity (5 and 25 μmol DATS) |
24 |
| F344 Rats (male) | DEN7 + PH8 liver model |
150 mg/kg DATS, gavage five times/wk for 8 wk |
Increase in number and area of GST-P positive foci in the liver |
25 |
1
Abbreviations: BP, benzo[a]pyrene;
2
DATS, diallyl trisulfide;
3
DATS-PBCA-NP, polybutylcyanoacrylate nanoparticle of DATS;
4
TRAMP, Transgenic Adenocarcinoma of Mouse Prostate;
5
DMBA, 7,12-dimethylbenz(a)anthracene;
6
TPA, 12-O-tetradecanoylphorbol-13-acetate;
7
DEN, diethylnitrosamine;
8
PH, partial hepatectomy.